Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As....
-
Upload
emily-stewart -
Category
Documents
-
view
227 -
download
2
Transcript of Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As....
![Page 1: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/1.jpg)
Prostate cancer
As. MUDr. Jan Pokorný, FEBU
Head: Doc. MUDr. Robert Grill, Ph.D.
Vice-head: As. MUDr. Lukáš Bittner, FEBU
Urologická klinika 3. LF UK a FNKV
![Page 2: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/2.jpg)
Prostate cancer
Epidemiology:
Incidence:
ČR 80/100 000
USA 120/100 000
Mortality:
ČR 15/100 000
![Page 3: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/3.jpg)
Prostate cancer
Epidemiology:
ČR
![Page 4: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/4.jpg)
Prostate cancer
Epidemiology:
Prostate cancer:
EU – 2nd in men mortality for cancer (1st lung cancer)
USA – 1st in men mortality for cancer
![Page 5: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/5.jpg)
Prostate cancer
Epidemiology:
Risk factors:
Increasing age, race (afroamericans), heredity
Exogenous factors:
Diete, UV radiation, alcohol consumption, risk sexual behavior, infection (HPV?)
![Page 6: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/6.jpg)
Prostate cancer
Epidemiology:
Increasing age:
The prostate cancer incidence in per cent generaly correlates to the patient´s age
![Page 7: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/7.jpg)
Prostate cancer
Epidemiology:
Basic check-up:
Discussion about the mass screening
Expenses
Unapparent (asymptomatic) tumors treatment
![Page 8: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/8.jpg)
Prostate cancer
Epidemiology:
Basic check-up:
Recommended:
Screening in risk population – positive family history
Positive clinical symptoms In patients who actively visit doctor and ask for
check-up
![Page 9: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/9.jpg)
Prostate cancer
Epidemiology:
Basic check-up:
Recommended:
Digital rectal examination in all men in all time
PSA only in recommended case (previous slide)
![Page 10: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/10.jpg)
Prostate cancer
Epidemiology:
Basic check-up:
Recommended:
Start PSA test between 45-50 years
Start PSA test in the positive family history case between 40-45 years
![Page 11: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/11.jpg)
Prostate cancer
Epidemiology:
Basic check-up:
Recommended:
In patient unfit for treatment (age, co-morbidity, weak life prognosis) there is NO INDICATION FOR PSA TESTING !!!
![Page 12: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/12.jpg)
Prostate cancer
Diagnosis:
Basic exams:
Digital rectal exam (DRE)
Prostate specific antigen (PSA)
![Page 13: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/13.jpg)
Prostate cancer
Diagnosis:
DRE:
![Page 14: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/14.jpg)
Prostate cancer
Diagnosis:
DRE:
Prostate shape, volume, consistence, demarcation
Semen vesicules examination
Bimanual palpation (in anesthesia)
![Page 15: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/15.jpg)
Prostate cancer
Diagnosis: DRE:
95 % of cancer originates from the peripheral zone of prostate
Suitable for palpation
![Page 16: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/16.jpg)
Prostate cancer
Diagnosis:
Prostate specific antigen (PSA):
33 kD molecular weigh glycoprotein
(Proteases enzyme)
Gene in 19th chromosome
Half-life period 3-5 days
![Page 17: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/17.jpg)
Prostate cancer
Diagnosis:
Prostate specific antigen (PSA):
Produced almost exclusively by the epithelial cells of the prostate
Prostate-specific marker, no cancer-specific
High sperm concentration
![Page 18: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/18.jpg)
Prostate cancer
Diagnosis:
Prostate specific antigen (PSA):
Venous blood sample The exact cut-off level of what is considered to be
a normal PSA value has yet to be determined Generally used cut-off level: 4-4.2 ng/ml Values of approximately < 2-3 ng/ml are often
used for younger men
![Page 19: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/19.jpg)
Prostate cancer
Diagnosis:
Prostate cancer diagnosis:
PSA elevation or DRE suspicion
Prostate biopsy – Transrectal USG
(TRUS biopsy)
PCA3 (Prostate Cancer Antigen 3)
![Page 20: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/20.jpg)
Prostate cancer
Diagnosis:
TRUS prostate biopsy:
Prostate morphology Peripheral zone biopsy Min. of 12 samples, according to prostate volume
correction In case of negative first biopsy repet one is
needed
![Page 21: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/21.jpg)
Prostate cancer
Diagnosis:
TRUS prostate biopsy:
Biopsy gun
![Page 22: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/22.jpg)
Prostate cancer
Diagnosis: Prostate Cancer Antigen 3 (PCA3):
Genetic marker Cancer - specific
Urine sampled after DRE
Additional test, no standard
![Page 23: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/23.jpg)
Prostate cancer
Diagnosis: Prostate Cancer Antigen 3 (PCA3):
Indications: PSA elevation and negative prostate biopsy
Decision on re-biopsy
No treatment in PCA3 elevation only
![Page 24: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/24.jpg)
Prostate cancer
Diagnosis:
Prostate Cancer Antigen 3 (PCA3):
Some studies present the PCA3 level and Gleason Score correlation (tumor aggressiveness)
![Page 25: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/25.jpg)
Prostate cancer
Diagnosis:
Morphology:
Histological types:
Acinar adenocarcinoma Papilar (ductal) carcinoma Small cell carcinoma Ring cell carcinoma Sarcomatoid carcinoma (No PSA production)
![Page 26: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/26.jpg)
Prostate cancer
Diagnosis:
Grading:
Gleason grade
![Page 27: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/27.jpg)
Prostate cancer
Diagnosis:
Grading:
Gleason score: The Gleason score is the sum of the most
dominant and second most dominant (in terms of volume) Gleason grade. If only one grade is present, the primary grade is doubled.
Examples include: GS 2+2, GS 3+4, GS 4+3 etc.
![Page 28: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/28.jpg)
Prostate cancer
Diagnosis:
Grading:
Gleason scoce correlates to the tumor dedifferentiation (aggressiveness)
![Page 29: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/29.jpg)
Prostate cancer
Diagnosis:
Staging: DRE TRUS
CT scan and bone scan in PSA value > 20 ng/ml (in case of GS ≥ 7 even in PSA value > 10 ng/ml)
MRI
![Page 30: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/30.jpg)
Prostate cancer
Diagnosis:
Staging:
TNM classification: T1 – Clinically unapparent tumour not palpable or
visible by imaging T2 – Tumour confined within the prostate T3 – Tumour extends through the prostatic
capsule T4 – Tumour is fixed or invades adjacent
structures other than seminal vesicles
![Page 31: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/31.jpg)
Prostate cancer
Diagnosis:
Staging:
TNM classification:
N1 – Lymph nodes involvement
M1 – Distant metastases (non-regional lymph nodes, bones, liver, lungs)
![Page 32: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/32.jpg)
Prostate cancer
Diagnosis:
Staging:
![Page 33: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/33.jpg)
Prostate cancer
Diagnosis:
Staging:
![Page 34: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/34.jpg)
Prostate cancer
Diagnosis:
Prognotic factors:
Gleason score (Tumor aggressiveness) PSA level Age and biological condition
![Page 35: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/35.jpg)
Prostate cancer
Treatment: Localised prostate cancer (T1-T2):
Watchful Waiting / Active Monitoring Surgery – Radical Prostatectomy Radiation therapy (Tele, Brachy) Experimental – Kryosurgery, HIFU ( High
Intensity Focused Ultrasound)
![Page 36: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/36.jpg)
Prostate cancer
Treatment:
Watchful waiting (WW): Deferred treatment Treatment starts in case of clinical symptoms
developement No cure intention Suitable for patients with shorter life expectancy
![Page 37: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/37.jpg)
Prostate cancer
Treatment:
Active surveillance or monitoring (AS): Deferred treatment with cure intention Active monitoring of tumor activity (PSA, repet
TRUS biopsy – progression of number of positive samples, Gleason Score progression etc.)
Treatment starts at the moment of progression Well-informed patient only
![Page 38: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/38.jpg)
Prostate cancer
Treatment:
Radical prostatectomy:
Complete prostate, prostate capsule, vesicles and prostate part of urethra removal
Lymphadenectomy only in indicated cases
![Page 39: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/39.jpg)
Prostate cancer
Treatment:
Radical prostatectomy:
Retropubic access
Open surgery Laparoscopy Robot - assisted
![Page 40: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/40.jpg)
Prostate cancer
Treatment:
Radical prostatectomy:
T1-2 stages
„Younger“ patients – life expectancy > 10 years
![Page 41: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/41.jpg)
Prostate cancer
Treatment:
Radical radiation therapy:
Teleradiotherapy:
External beam of radiation of prostate, vesicles and surrounding tissues, in special cases of regional lymph nodes
![Page 42: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/42.jpg)
Prostate cancer
Treatment:
Teleradiotherapy:
Linear accelerators Three-dimensional conformal radiotherapy (3D-
CRT) and intensity modulated external beam radiotherapy (IMRT)
Dose escalation Adverse events minimalization
![Page 43: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/43.jpg)
Prostate cancer
Treatment:
Teleradiotherapy:
Innovative techniques:
Proton beam accelerators Carbon ion beam accelerators
![Page 44: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/44.jpg)
Prostate cancer
Treatment:
Teleradiotherapy:
T1-2 stages and no plan of radical prostatectomy
T3-T4, N1 stages
![Page 45: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/45.jpg)
Prostate cancer
Treatment:
Transperineal Brachytherapy:
Effective technique in T1-2 stages, PSA ≤ 10 ng/ml, GS ≤ 6 and prostate volume ≤ 50-60 ml
![Page 46: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/46.jpg)
Prostate cancer
Treatment:
Transperineal Brachytherapy:
Transperineal access, USG guided technique
Permanent radioactive implats application (Palladium-103)
![Page 47: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/47.jpg)
Prostate cancer
Treatment:
Transperineal Brachytherapy:
Local anesthesia only
One-shot application
![Page 48: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/48.jpg)
Prostate cancer
Treatment: Local advanced prostate cancer (T3-T4, N1):
Watchful waiting
Radiation therapy (Teleradiotherapy)
![Page 49: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/49.jpg)
Prostate cancer
Treatment:Metastatis prostate cancer:
Watchful waiting Hormonal therapy Chemotherapy Palliative therapy
![Page 50: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/50.jpg)
Prostate cancer
Treatment:
Hormonal therapy: Stage M1
Endogeneous androgen production: Testicles 90 – 95 % Adrenal glands 5 – 10 %
![Page 51: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/51.jpg)
Prostate cancer
Treatment:
Hormonal therapy:
Testosterone is essential
for the prostate tissue
growth and prostate
cancer growth as well
http://www.oncoprof.net
![Page 52: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/52.jpg)
Prostate cancer
Treatment:
Hormonal therapy:
LHRH analogs – central blocade Antinadrogens – peripheral blocade Ketokonazole – adrenal production blocade Surgical– bilateral orchiectomy Combinations
![Page 53: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/53.jpg)
Prostate cancer
Treatment:
Chemotherapy: Taxans – Docetaxel, Cabazitaxel Estramustin
Treatment of relapse after hormonal therapy in stage M1
![Page 54: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/54.jpg)
Prostate cancer
Treatment:
Palliative therapeutic options:
Bone metastases:
(Bone resorption inactivation) Bisphosphonates Denosumab
Painful bone metastases – i.v. aplication of radionuclides (Stroncium)
![Page 55: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/55.jpg)
Prostate cancer
Treatment:
Palliative therapeutic options:
Urinaty retention:
TURP (Transurethral Prostate Resection) Urethral catheter, epicystostomia Ureteral stents Nephrostomy tube
![Page 56: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/56.jpg)
Prostate cancer
Treatment:
Palliative therapeutic options:
Opoids Blood supplementation Corticosteroids Surgical treatment of pathological bone fractures
and vertebral compression
![Page 57: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/57.jpg)
Prostate cancer
Follow-up :
Basic periodic exam.:
PSA
DRE
![Page 58: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/58.jpg)
Prostate cancer
Follow-up :
PSA elevation - restaging
CT
Bone scan
![Page 59: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/59.jpg)
Prostate cancer
Follow-up :
In special cases:
PET – CT
MRI
![Page 60: Prostate cancer As. MUDr. Jan Pokorný, FEBU Head: Doc. MUDr. Robert Grill, Ph.D. Vice-head: As. MUDr. Lukáš Bittner, FEBU Urologická klinika 3. LF UK a.](https://reader035.fdocuments.in/reader035/viewer/2022081504/56649d9c5503460f94a85a63/html5/thumbnails/60.jpg)
Prostate cancer
Prognosis:
Generally excellent (in T1-N1 stage generally complete cure)
Majority of patients in M1 stage survive years!
Prognosis estimation: Entering Gleason score, PSA, biological condition